3 results
To compare the severity of retinopathy of prematurity (ROP) among treated infants with an untreated control population, matched for GA at birth while confirming the dose of rhIGF 1/rhIGFBP-3 is safe and efficacious.
Phase I:Primary Objective:To determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK-positive solid tumors RP2D and, if applicable, the MTD as determined by incidence of DLTs during Cycle 1, overall safety profile, PK…
The primary objective of this study is to assess the effect of OHB-607 on reducing the burden of CLD, as indicated by a reduction in the incidence of severe BPD at 36 weeks (±3 days) PMA, or death, whichever comes first as compared to the Standard…